{"commentary":{"count":55,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":38,"youtube":8,"podcast":8,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05571293\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NEST-1","nct_id":"NCT05571293","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nest-1-nct05571293. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"NEST-1","arms":[{"description":"Botensilimab and balstilimab are both monoclonal antibodies that are administered intravenously. Two doses of balstilimab (240 mg IV), will be administered approximately 2 weeks apart. A single dose of botensilimab (75 mg IV) will be administered on the same day as the first dose of balstilimab. Surgical resection will occur 1-6 weeks following the second dose of balstilimab.","label":"Cohort A: Botensilimab and balstilimab (bot/bal)","type":"EXPERIMENTAL"},{"description":"Botensilimab and balstilimab are both monoclonal antibodies that are administered intravenously. Four doses of balstilimab (240 mg IV), will be administered approximately 2 weeks apart. A single dose of botensilimab (75 mg IV) will be administered on the same day as the first dose of balstilimab. Surgical resection will occur 1-6 weeks following the fourth dose of balstilimab.","label":"Cohort B:","type":"EXPERIMENTAL"},{"description":"Botensilimab and balstilimab are both monoclonal antibodies that are administered intravenously. Four doses of balstilimab (240 mg IV), will be administered approximately 2 weeks apart. A single dose of botensilimab (75 mg IV) will be administered on the same day as the first dose of balstilimab. Surgical resection will occur 1-6 weeks following the fourth dose of balstilimab. Cohort C only includes patients with dMMR/MSI-High colorectal cancer.","label":"Cohort C:","type":"EXPERIMENTAL"}],"collaborators":["Agenus Inc."],"completion_date":{"date":"2024-11-14","type":"ACTUAL"},"conditions":["Colorectal Neoplasms"],"enrollment":{"count":26,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Botensilimab","type":"DRUG"},{"name":"Balstilimab","type":"DRUG"}],"last_update":"2026-10-09","lead_sponsor":"Weill Medical College of Cornell University","official_title":"Novel Exploratory Study to Test Combination of Botensilimab and Balstilimab Immunotherapy in Resectable Colorectal Cancer Patients","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-11-14","type":"ACTUAL"},"primary_outcomes":[{"measure":"Cohort A and B: Pathological Overall Response (pOR) Rate Determined by Analysis of Tissue Resected During Surgery Reported by Cohort","timeFrame":"Immediately following surgical resection of the primary tumor"},{"measure":"Cohort A: Number of Participants Who Experience Potentially Treatment-related SAEs According to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 at 90 Days Following the Last Treatment With Balstilimab or Botensilimab","timeFrame":"From date of last dose of study drug up to 90 days after"},{"measure":"Cohort A: Number of Participants Who Experience Treatment-related Complications Leading to Delays of 12 Weeks or More in Surgery After Treatment Initiation (Day 0)","timeFrame":"12 weeks after treatment initiation date (Day 0)"},{"measure":"Cohort C: Composite Rate of Clinical Complete Response or Major Pathological Response at 6 Months","timeFrame":"6 months"}],"references":[],"start_date":{"date":"2023-03-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Combination Immunotherapy in Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT05571293"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nest-1-nct05571293"}